(b) The respondents are the following entities alleged to be in violation of section 337, and are the parties upon which the complaint is to be served:
TCL Industries Holdings Co., Ltd., 22nd Floor, TCL Technology Building, Huifeng Third Road, Zhongkai Development Zone, Huizhou, Guangdong, China 516006
TCL Industries Holdings (H.K.) Limited, 8th Floor, Building 22E, Phase Three, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong
TCL Electronics Holdings Limited, f/k/a TCL Multimedia Technology Holdings, Ltd., 7/F, Building 22E, 22 Science Park East Avenue, Hong Kong Science Park, Sha Tin, New Territories, Hong Kong
TCL Technology Group Corporation, TCL Technology Building, No. 17, Huifeng Third Road, Zhongkai High-tech Zone, Huizhou, Guangdong, China 516006
TCL MOKA International Limited, 7/F, Building 22E, 22 Science Park East Avenue, Hong Kong Science Park, Sha Tin, New Territories, Hong Kong
TCL Holding (BVI) Limited, 5/F, Building 22E, 22 Science Park East Avenue, Hong Kong Science Park, Sha Tin, New Territories, Hong Kong
TCL King Electrical Appliances (Huizhou) Co., Ltd. No. 78, Huifeng Fourth Road, Zhongkai Development Zone, Huizhou, Guangdong, China 516006
Shenzhen TCL New Technologies Co., Ltd., 9th Floor, TCL Electronics Holdings Limited Building, TCL International E City, No. 1001, Zongshan Park Road, Nanshan District, Shenzhen, Guangdong, China 518067
TCL MOKA International Limited, 7/F Hong Kong Science Park, Building 22 E, 22 Science Park East Avenue, Sha Tin, New Territories, Hong Kong
Manufacturas Avanzadas SA de CV, Blvd. Independencia #2151, Parque Industrial Salvacar, Ciudad Juárez, Chihuahua, Mexico 32574
TCL Electronics Mexico, S de RL de CV, Av. Insurgentes Sur 1425, Insurgentes Mixcoac, Benito Juarez, Distrito Federal, Mexico 03920
TCL Overseas Marketing Ltd., 5/F, Building 22E, 22 Science Park East Avenue, Hong Kong Science Park, Sha Tin, New Territories, Hong Kong
Realtek Semiconductor Corp., No. 2, Innovation Road II, Hsinchu Science Park, Hsinchu 300, Taiwan

(4) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge.

The Office of Unfair Import Investigations will not participate as a party to this investigation.

Responses to the complaint and the notice of investigation must be submitted by the named respondents in accordance with section 210.13 of the Commission’s Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.26(e) and 210.13(a), as amended in 85 FR 15798 (March 19, 2020), such responses will be considered by the Commission if received not later than 20 days after the date of service by the complainants of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown.

Failure of a respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent.

By order of the Commission.
Issued: June 1, 2022.

Lisa Barton,
Secretary to the Commission.

By order of the Commission.
Issued: June 1, 2022.

Lisa Barton,
Secretary to the Commission.

DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1024]

Bulk Manufacturer of Controlled Substances Application: Stepan Company

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Stepan Company has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before August 8, 2022. Such persons may also file a written request.

INTERNATIONAL TRADE COMMISSION

Certain Coated Paper Suitable for High-Quality Print Graphics Using Sheet-Fed Presses from China and Indonesia

Determination

On the basis of the record developed in the subject five-year reviews, the United States International Trade Commission (“Commission”) determines, pursuant to the Tariff Act of 1930 (“the Act”), that revocation of the countervailing and antidumping duty orders on certain coated paper suitable for high-quality print graphics using sheet-fed presses from China and Indonesia would be likely to lead to continuation or recurrence of material injury to an industry in the United States within a reasonably foreseeable time.

Background

The Commission instituted these reviews on December 1, 2021 (86 FR 66272) and determined on March 7, 2022, that it would conduct expedited reviews (87 FR 22231, April 14, 2022).

The Commission made these determinations pursuant to section 751(c) of the Act (19 U.S.C. 1675(c)). It completed and filed its determinations in these reviews on June 2, 2022. The views of the Commission are contained in USITC Publication 5330 (June 2022), entitled Certain Coated Paper Suitable for High-Quality Print Graphics Using Sheet-Fed Presses from China and Indonesia (Inv. Nos. 701–TA–470–471 and 731–TA–1169–1170 (Second Review)).

By order of the Commission.
Issued: June 1, 2022.

Lisa Barton,
Secretary to the Commission.

BILLING CODE 7020–02–P
for a hearing on the application on or before August 8, 2022.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on March 9, 2022, Pisgah Laboratories Inc., 3222 Old Hendersonville Highway, Pisgah Forest, North Carolina 28768, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cocaine</td>
<td>9041</td>
<td>II</td>
</tr>
<tr>
<td>Egonine</td>
<td>9180</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to bulk manufacture the listed controlled substances for the internal use intermediates or for sale to its customers.

Kristi O’Malley, 
Assistant Administrator.

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA–1021]

**Bulk Manufacturer of Controlled Substances Application: Pisgah Laboratories Inc.**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Pisgah Laboratories Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before August 8, 2022. Such persons may also file a written request for a hearing on the application on or before August 8, 2022.

**ADDRESS:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on March 9, 2022, Pisgah Laboratories Inc., 3222 Old Hendersonville Highway, Pisgah Forest, North Carolina 28768, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Drug code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-Bromo-2,5-dimethoxyphenethylamine</td>
<td>7392</td>
<td>I</td>
</tr>
<tr>
<td>Methylene (3,4-Methylenedioxy-N-methylcathinone)</td>
<td>7540</td>
<td>I</td>
</tr>
<tr>
<td>Difenoxyxylate</td>
<td>9168</td>
<td>II</td>
</tr>
<tr>
<td>Levorphanol</td>
<td>9170</td>
<td>II</td>
</tr>
<tr>
<td>Meperidine</td>
<td>9739</td>
<td>II</td>
</tr>
<tr>
<td>Methadone</td>
<td>9780</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to bulk manufacture the above-listed controlled substances in bulk for distribution to its customers. No other activities for these drug codes are authorized for this registration.

Kristi O’Malley, 
Assistant Administrator.

**DEPARTMENT OF JUSTICE**

**Notice of Proposed Interim Settlement and Crediting Agreement Under Comprehensive Environmental Response, Compensation, and Liability Act**

As of May 25, 2022, the United States Fish and Wildlife Service (“USFWS”), on behalf of the Department of the Interior, the National Oceanic and Atmospheric Administration (“NOAA”), on behalf of the Department of Commerce, (collectively, the “Trustees”), the Department of Justice, and potentially responsible party (“PRP”) BASF Corporation (“BASF”) signed a proposed non-judicial Interim Settlement and Crediting Agreement concerning early natural resource restoration work under the Comprehensive Environmental Response, Compensation, and Liability Act (“CERCLA”), 42 U.S.C. 9601 et seq., for a five-acre property in East Newark, New Jersey. The United States contends BASF and other PRPs are liable for natural resource damages under Section 107(a) of CERCLA, 42 U.S.C. 9607(a), concerning the Diamond Alkali Superfund Site, including Newark Bay and the upstream 17 mile stretch of the Passaic River, and the Berry’s Creek Study Area, Bergen County, New Jersey (collectively “the Sites”). The proposed agreement facilitates early natural resource restoration work, and provides for credit for accomplished early restoration work, in advance of the